{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:14:07Z","timestamp":1788020047305,"version":"build-2784847793"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.45446","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:32:36Z","timestamp":1643301156000},"page":"e2145446","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors"],"prefix":"10.1001","volume":"5","author":[{"given":"Douglas W.","family":"Blayney","sequence":"first","affiliation":[{"name":"Stanford Cancer Institute, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Mohanlal","sequence":"additional","affiliation":[{"name":"BeyondSpring Pharmaceuticals, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hryhoriy","family":"Adamchuk","sequence":"additional","affiliation":[{"name":"MI Kriviy Rih Oncology Dispensary, Krivoy Rog, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry Valikovich","family":"Kirtbaya","sequence":"additional","affiliation":[{"name":"SBI of Healthcare Oncology Dispensary 2, Ministry of Healthcare of Krasnodar Region 38, Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chen","sequence":"additional","affiliation":[{"name":"TCM Groups, Inc, Berkeley Heights, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Du","sequence":"additional","affiliation":[{"name":"Dalian Wanchun Bulin Pharmaceuticals Limited, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ogenstad","sequence":"additional","affiliation":[{"name":"Statogen Consulting, LLC, Wake Forest, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Ginn","sequence":"additional","affiliation":[{"name":"Statogen Consulting, LLC, Wake Forest, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"BeyondSpring Pharmaceuticals, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Third of Internal Medicine Department, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"18","key":"zoi211254r1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia.","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi211254r2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.6004\/jnccn.2015.0014","article-title":"Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.","volume":"13","author":"Dinan","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"zoi211254r3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non\u2013small-cell lung cancer previously treated with chemotherapy.","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi211254r4","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","article-title":"Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.","volume":"31","author":"Aarts","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi211254r5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JOP.091094","article-title":"Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non\u2013small-cell lung cancer, ovarian cancer, and non-Hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase 2 studies.","volume":"6","author":"Burris","year":"2010","journal-title":"J Oncol Pract"},{"issue":"23","key":"zoi211254r6","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer.","volume":"363","author":"Mart\u00edn","year":"2010","journal-title":"N Engl J Med"},{"key":"zoi211254r7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.6-suppl_3-5","article-title":"Taxane\/anthracycline combinations: setting a new standard in breast cancer?","volume":"6","author":"Nabholtz","year":"2001","journal-title":"Oncologist"},{"issue":"5","key":"zoi211254r8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4174\/astr.2018.94.5.223","article-title":"Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.","volume":"94","author":"Lee","year":"2018","journal-title":"Ann Surg Treat Res"},{"issue":"10","key":"zoi211254r9","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","article-title":"Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.","volume":"23","author":"Masuda","year":"2015","journal-title":"Support Care Cancer"},{"issue":"3","key":"zoi211254r10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer.","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi211254r11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi211254r12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"zoi211254r13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-019-03998-w","article-title":"Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.","volume":"85","author":"Tonra","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 15","key":"zoi211254r14","article-title":"A comparison of CD34+ mobilization effects of standard dose pegfilgrastim (Peg) versus low-dose peg combined with plinabulin.","volume":"38","author":"Blayney","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi211254r15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi211254r16","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky053","article-title":"Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the Fence score.","volume":"2","author":"Aagaard","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"zoi211254r17","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory.","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"issue":"2","key":"zoi211254r19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/ajco.2014.10.issue-2","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"zoi211254r20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jclinepi.2015.02.011","article-title":"Summary scores captured changes in subjects\u2019 QoL as measured by the multiple scales of the EORTC QLQ-C30.","volume":"68","author":"Phillips","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"zoi211254r22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"zoi211254r23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ebiom.2017.03.029","article-title":"Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment.","volume":"18","author":"Cassidy","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"zoi211254r24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.","volume":"6","author":"Lalani","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"13","key":"zoi211254r25","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.celrep.2019.08.057","article-title":"GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses.","volume":"28","author":"Kashyap","year":"2019","journal-title":"Cell Rep"},{"issue":"suppl 15","key":"zoi211254r26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2021.39.15_suppl.533","article-title":"Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.","volume":"39","author":"Blayney","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi211254r27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"zoi211254r18","volume-title":"The Brief Pain Inventory User Guide","author":"Cleeland","year":"2009"},{"key":"zoi211254r21","volume-title":"The EORTC QLQ-C30 Manuals, Reference Values and Bibliography Brussels","author":"EORTC Quality of Life Group","year":"2002"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2788453\/blayney_2022_oi_211254_1643157287.55588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:32:47Z","timestamp":1643301167000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2788453"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.45446","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}